Search results

Found 5,009 pages
AUTHOR: Selina McKee

Your search yielded no results

  • Check if your spelling is correct.
  • Remove quotes around phrases to search for each word individually. bike shed will often show more results than "bike shed".
  • Consider loosening your query with OR. bike OR shed will often show more results than bike shed.

AZ buys Ionis’ NASH candidate

AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/az_buys_ionis_nash_candidate_1231077

Fresenius pulls out of $4.3bn Akorn merger

German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/fresenius_pulls_out_of_$4.3bn_akorn_merger_1232855

CHMP rejects AB Science’s ALS drug

AB Science’s share price has taken a hit after European Medicine Agency's advisors rejected approval of masitinib for amyotrophic lateral sclerosis. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/chmp_rejects_ab_sciences_als_drug_1232829

Concept buys Scottish CRO Aquila

Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/concept_buys_scottish_cro_aquila_1209900

EU expands scope of Amgen’s Xgeva

European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/eu_expands_scope_of_amgens_xgeva_1230285

AZ lung cancer combo fails to hit targets

A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/az_lung_cancer_combo_fails_to_hit_targets_1233008

Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/alexion_to_buy_wilson_for_$855m_1231334

NICE no for Roche’s Alecensa

The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/nice_no_for_roches_alecensa_1231330

NICE ‘no’ for Roche’s Ocrevus

The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/nice_no_for_roches_ocrevus_1230626

FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug

US regulatory advisors are backing approval the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA). - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/fda_advisors_back_lillyincytes_rheumatoid_arthritis_drug_1233030

Latest jobs

View all

What job are you looking for?

This field is required.

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download